Literature DB >> 32231501

Agranulocytosis Induced by Tamoxifen in a Breast Cancer Patient.

Hugo Herrscher1, Julie Leblanc1, Thierry Petit1.   

Abstract

BACKGROUND: The main side effects of tamoxifen are menopausal symptoms. We report a case of agranulocytosis induced by tamoxifen in a 33-year-old woman treated in the adjuvant setting. CASE
PRESENTATION: Ten days after the beginning of tamoxifen treatment, the patient complained of asthenia and mucositis. Blood testing showed a grade 4 neutropenia (0.06 G/L) without any other major hematologic disorder. Tamoxifen was discontinued, and the patient received granulocyte colony-stimulating factor. Within 2 days, she recovered to a normal granulocyte count. Tamoxifen was then switched to the combination of ovarian suppression (triptorelin) and aromatase inhibitor (anastrozole).
CONCLUSION: Agranulocytosis is a very rare adverse event of tamoxifen.
Copyright © 2019 by S. Karger AG, Basel.

Entities:  

Keywords:  Agranulocytosis; Endocrine therapy; Tamoxifen; Toxicity

Year:  2019        PMID: 32231501      PMCID: PMC7098272          DOI: 10.1159/000500708

Source DB:  PubMed          Journal:  Breast Care (Basel)        ISSN: 1661-3791            Impact factor:   2.860


  12 in total

1.  Tamoxifen-associated hepatocellular damage and agranulocytosis.

Authors:  C K Ching; P G Smith; R G Long
Journal:  Lancet       Date:  1992-04-11       Impact factor: 79.321

Review 2.  Grade 3 trastuzumab-induced neutropenia in breast cancer patient.

Authors:  Ehab A Ghani; Ian Kerr; Reyad Dada
Journal:  J Oncol Pharm Pract       Date:  2013-06-26       Impact factor: 1.809

3.  Fatal neutropenia associated with long-term tamoxifen therapy.

Authors:  V Miké; V E Currie; T S Gee
Journal:  Lancet       Date:  1994-08-20       Impact factor: 79.321

Review 4.  Non-chemotherapy drug-induced neutropenia - an update.

Authors:  Emmanuel Andrès; Rachel Mourot-Cottet
Journal:  Expert Opin Drug Saf       Date:  2017-09-17       Impact factor: 4.250

5.  Adjuvant ovarian suppression in premenopausal breast cancer.

Authors:  Prudence A Francis; Meredith M Regan; Gini F Fleming; István Láng; Eva Ciruelos; Meritxell Bellet; Hervé R Bonnefoi; Miguel A Climent; Gian Antonio Da Prada; Harold J Burstein; Silvana Martino; Nancy E Davidson; Charles E Geyer; Barbara A Walley; Robert Coleman; Pierre Kerbrat; Stefan Buchholz; James N Ingle; Eric P Winer; Manuela Rabaglio-Poretti; Rudolf Maibach; Barbara Ruepp; Anita Giobbie-Hurder; Karen N Price; Marco Colleoni; Giuseppe Viale; Alan S Coates; Aron Goldhirsch; Richard D Gelber
Journal:  N Engl J Med       Date:  2014-12-11       Impact factor: 91.245

Review 6.  Toxicity and adverse effects of Tamoxifen and other anti-estrogen drugs.

Authors:  Geniey Yang; Somaira Nowsheen; Khaled Aziz; Alexandros G Georgakilas
Journal:  Pharmacol Ther       Date:  2013-05-24       Impact factor: 12.310

7.  Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.

Authors:  Olivia Pagani; Meredith M Regan; Barbara A Walley; Gini F Fleming; Marco Colleoni; István Láng; Henry L Gomez; Carlo Tondini; Harold J Burstein; Edith A Perez; Eva Ciruelos; Vered Stearns; Hervé R Bonnefoi; Silvana Martino; Charles E Geyer; Graziella Pinotti; Fabio Puglisi; Diana Crivellari; Thomas Ruhstaller; Eric P Winer; Manuela Rabaglio-Poretti; Rudolf Maibach; Barbara Ruepp; Anita Giobbie-Hurder; Karen N Price; Jürg Bernhard; Weixiu Luo; Karin Ribi; Giuseppe Viale; Alan S Coates; Richard D Gelber; Aron Goldhirsch; Prudence A Francis
Journal:  N Engl J Med       Date:  2014-06-01       Impact factor: 91.245

Review 8.  Contribution of modelling chemotherapy-induced hematological toxicity for clinical practice.

Authors:  Diane Testart-Paillet; Pascal Girard; Benoit You; Gilles Freyer; Christian Pobel; Brigitte Tranchand
Journal:  Crit Rev Oncol Hematol       Date:  2007-04-05       Impact factor: 6.312

9.  Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials.

Authors:  C Davies; J Godwin; R Gray; M Clarke; D Cutter; S Darby; P McGale; H C Pan; C Taylor; Y C Wang; M Dowsett; J Ingle; R Peto
Journal:  Lancet       Date:  2011-07-28       Impact factor: 79.321

10.  Prognostic Effects of Adjuvant Chemotherapy-Induced Amenorrhea and Subsequent Resumption of Menstruation for Premenopausal Breast Cancer Patients.

Authors:  Se Jeong Jeon; Jae Il Lee; Myung Jae Jeon; Maria Lee
Journal:  Medicine (Baltimore)       Date:  2016-04       Impact factor: 1.889

View more
  1 in total

1.  The Optimized Formulation of Tamoxifen-Loaded Niosomes Efficiently Induced Apoptosis and Cell Cycle Arrest in Breast Cancer Cells.

Authors:  Iman Akbarzadeh; Mahsa Farid; Mehrnoosh Javidfar; Negar Zabet; Bahare Shokoohian; Mandana Kazem Arki; Anastasia Shpichka; Hassan Noorbazargan; Hamid Asadzadeh Aghdaei; Nikoo Hossein-Khannazer; Peter Timashev; Pooyan Makvandi; Massoud Vosough
Journal:  AAPS PharmSciTech       Date:  2022-01-19       Impact factor: 3.246

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.